ARB Impurities Less Dangerous Than FDA First Believed, Woodcock Says

Drug Industry Daily
A A
CDER Director Janet Woodcock said Wednesday that the agency believes the risks posed to patients by nitrosomine impurities in blood pressure drugs are “likely much lower” than initially thought.

To View This Article:

Login

Subscribe To Drug Industry Daily